{
    "nct_id": "NCT03061201",
    "official_title": "A PHASE 1/2, OPEN-LABEL, ADAPTIVE, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF SB-525 (PF-07055480) (RECOMBINANT AAV2/6 HUMAN FACTOR 8 GENE THERAPY) IN ADULT SUBJECTS WITH SEVERE HEMOPHILIA A",
    "inclusion_criteria": "* Male ≥18 years of age\n* Severe hemophilia A (past evidence of circulating FVIII activity of < 1% normal)\n* Treated or exposed to FVIII concentrates or cryoprecipitate for at least 150 exposure days\n* ≥12 bleeding episodes if receiving on-demand therapy over the preceding 12 months\n* Agree to use double barrier contraceptive until at least 3 consecutive semen samples are negative for AAV 2/6 after SB-525 infusion\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Presence of neutralizing antibodies\n* Current inhibitor, or history of FVIII inhibitor (except for transient low titer inhibitor detected in childhood)\n* History of hypersensitivity response to FVIII\n* History of Hepatitis B or HIV-1/2 infection\n* History of Hepatitis C, unless viral assays in two samples, collected at least 6 months apart, are negative\n* Evidence of any bleeding disorder in addition to hemophilia A\n* Markers of hepatic inflammation or overt or occult cirrhosis\n* History of chronic renal disease or creatinine ≥ 1.5 mg/dL\n* Presence of liver mass on magnetic resonance imaging (MRI), or, positive alpha fetoprotein\n* Presence of > grade 2 liver fibrosis on elastography for subjects with history of treated Hepatitis C or suspicion of chronic liver disease",
    "miscellaneous_criteria": ""
}